Mutated or dysregulated transcription factors represent a unique class of drug targets that
mediate aberrant gene expression, including blockade of differentiation and cell death gene …

Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

There is substantial heterogeneity among primary prostate cancers, evident in the spectrum
of molecular abnormalities and its variable clinical course. As part of The Cancer Genome …

The androgen-signaling axis plays a pivotal role in the pathogenesis of prostate cancer.
Since the landmark discovery by Huggins and Hodges, gonadal depletion of androgens has …

Background: Whether the genomic rearrangement transmembrane protease, serine 2
(TMPRSS2): v-ets erythroblastosis virus E26 oncogene homolog (ERG) has prognostic …

More than 95% of the 20,000 to 25,000 transcribed human genes undergo alternative RNA
splicing, which increases the diversity of the proteome. Isoforms derived from the same gene …

More than 1,000,000 men undergo prostate biopsy each year in the United States, most for
“elevated” serum prostate-specific antigen (PSA). Given the lack of specificity and unclear …

Background Patients with prostate cancer may present with metastatic or recurrent disease
despite initial curative treatment. The propensity of metastatic prostate cancer to spread to …

Abstract Context Prostate cancer (PCa) is a clinically heterogeneous disease with marked
variability in patient outcomes. Molecular characterization has revealed striking mutational …

TMPRSS2-ERG gene fusions occur in 50% of prostate cancers and result in the
overexpression of a chimeric fusion transcript that encodes a truncated ERG product …